SKU: DPH84 | Last Updated On: Sep 12 2019 | No. of Pages: 225 | Available Formats
The Oral Cavity Cancer market growth is driven by several factors such as rising prevalence of oral cancer, growing awareness towards oral diseases and increasing healthcare expenditures.
According to The American Cancer Society’s estimations, the number of oral cavities and oropharyngeal cancers cases in the US will reach about 51,540 cases in 2018, and an estimated 10,030 people will die of these cancers.
The market is hindered by several factors such as the high cost of treatment and risks of recurrence of cancer even after the procedure and related side effects. In 2015, according to the Dharamshila Hospital, India, the cost of the treatment of the oral cancers can range from USD 2,995 to USD 14,979.
According to the Oral Cancer Foundation, there were 49,750 cases diagnosed among Americans in 2017 with the oral oropharyngeal cancer. It is estimated that 9,750 deaths will be accounted for the same, killing one patient every 24 hours. Moreover, according to the Centres for Disease Control and Prevention, in 2015, the total U.S. healthcare expenditure accounted for 17.8% of the overall gross domestic product (GDP), which accounted for USD 3.2 trillion.
The global Oral Cavity Cancer market is segmented by Type into Verrucous Carcinoma, Squamous Cell Carcinoma, Lymphomas, Minor Salivary Gland Carcinomas, and Others. Among these, squamous cell carcinomas hold the largest market share. More than 90% of the cancers in the oral cavity and oropharynx are squamous cell carcinomas, also called squamous cell cancers which start in early forms of squamous cells, which are flat, scale-like cells that form the lining of the mouth and throat.
Geographically, the market is segmented into North America, South America, Europe, Asia-Pacific, and RoW. North America dominates the global Oral Cavity Cancer market due to rising per capita healthcare expenditures.
Europe is also growing with the second largest market for oral cancer treatment due to raising funds for research, developed healthcare infrastructure, and increasing healthcare expenditure. In 2014, according to the Cancer Research UK, 11,449 new cases of oral cancer were reported which caused 2,386 estimated death within the same year.
The major players of global Oral Cavity Cancer market include Bristol-Myers Squibb Company, Qilu Pharmaceutical Co., Teva Pharmaceutical Industries, Eli Lilly and Company, F. Hoffmann-La Roche, Merck & Co., Inc., Novartis AG, and Pfizer Inc.
In 2017, Merck & Co. Inc. announced the expansion on phase 3 study of KEYTRUDA, in August 2016. The U.S. Food and Drug Administration (FDA) approved KEYTRUDA for the treatment of patients of oral cancer (Squamous Cell Carcinoma).
The report covers the factors impacting the market, Porter 5 Forces, Market Share Analysis, Price trend analysis, Product Benchmarking, and company profiles.
Raw Material Suppliers/ Buyers
Product Suppliers/ Buyers
Industry Investors/Investment Bankers
Education & Research Institutes
Why purchase the report?
Visualize the composition of the Global Oral Cavity Cancer market across each indication, regarding type and applications, highlighting the critical commercial assets and players.
Identify commercial opportunities in Global Oral Cavity Cancer by analyzing trends and co-development deals.
Excel data sheet with thousands of data points of the Global Oral Cavity Cancer market – level 4/5 segmentation
PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study
Product mapping in excel for the critical Global Oral Cavity Cancer products of all major market players
1.1 Research methodology
1.2 Scope of the Report
3.1 Market Drivers
3.2 Market Restraints
3.3 Porters Five Forces Analysis
3.3.1 Suppliers Power
3.3.2 Buyer Power
3.3.3 Industry Competition
3.3.4 Threat of new Entrant
3.3.5 Threat of Substitutes
4.1. Segmentation by Type
4.1.1 Verrucous Carcinoma
4.1.2 Squamous Cell Carcinoma
4.1.4 Minor Salivary Gland Carcinomas
4.2. Segmentation by Treatment
22.214.171.124 5-Fluorouracil (5-FU)
4.2.3 Photodynamic Therapy (PDT)
126.96.36.199 Tumor Resection
188.8.131.52 Mohs Micrographic Surgery
4.3 Segmentation by End-User
4.3.1 Hospitals & Clinics
4.3.2 Research Centers
5.1. Asia Pacific
5.3.5. Rest of Asia Pacific
5.2.3. The UK
5.2.6. Rest of Europe
5.3. North America
5.3.1. The USA
5.3.4. Rest of North America
5.4. South America
5.4.3. Rest of South America
9.1 Market Share Analysis
9.2 Company Benchmarking
9.3 Key Strategies Adopted by Major Companies
10.1 Teva Pharmaceutical Industries Ltd.
10.2 Bristol-Myers Squibb Company
10.3 Qilu Pharmaceutical Co., Ltd.
10.4 Eli Lilly And Company
10.5 Merck & Co., Inc.
10.6 Hoffmann-La Roche Ltd
10.7 Pfizer Inc.
10.8 Novartis AG
11.2 List of Tables
11.3 Expert Panel Validation
11.5 Contact Us
*Note: Additional company profiles will be included on request